400.59 USD
-0.1 (-0.02%)
400.59 USD
0 (0%)
Taking everything into account, ALNY scores 6 out of 10 in our fundamental rating. ALNY was compared to 530 industry peers in the Biotechnology industry. ALNY has only an average score on both its financial health and profitability. ALNY is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! These ratings could make ALNY a good candidate for growth investing.
1. Profitability
1.1 Basic Checks
ALNY had positive earnings in the past year.
In the past year ALNY had a positive cash flow from operations.
ALNY had negative earnings in each of the past 5 years.
In the past 5 years ALNY reported 4 times negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 0.90%, ALNY belongs to the top of the industry, outperforming 88.49% of the companies in the same industry.
ALNY has a Return On Equity of 18.63%. This is amongst the best in the industry. ALNY outperforms 95.47% of its industry peers.
Looking at the Return On Invested Capital, with a value of 6.34%, ALNY belongs to the top of the industry, outperforming 92.08% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.9% | ||
| ROE | 18.63% | ||
| ROIC | 6.34% |
ROA(3y)-16.65%
ROA(5y)-19.71%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of ALNY (1.36%) is better than 88.87% of its industry peers.
Looking at the Operating Margin, with a value of 8.25%, ALNY belongs to the top of the industry, outperforming 90.57% of the companies in the same industry.
Looking at the Gross Margin, with a value of 83.90%, ALNY belongs to the top of the industry, outperforming 86.60% of the companies in the same industry.
In the last couple of years the Gross Margin of ALNY has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.25% | ||
| PM (TTM) | 1.36% | ||
| GM | 83.9% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.88%
GM growth 5Y-0.68%
2. Health
2.1 Basic Checks
ALNY has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
ALNY has more shares outstanding than it did 1 year ago.
ALNY has more shares outstanding than it did 5 years ago.
ALNY has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 6.24 indicates that ALNY is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 6.24, ALNY is doing good in the industry, outperforming 74.72% of the companies in the same industry.
ALNY has a debt to FCF ratio of 11.32. This is a negative value and a sign of low solvency as ALNY would need 11.32 years to pay back of all of its debts.
ALNY has a Debt to FCF ratio of 11.32. This is amongst the best in the industry. ALNY outperforms 90.57% of its industry peers.
A Debt/Equity ratio of 10.22 is on the high side and indicates that ALNY has dependencies on debt financing.
ALNY's Debt to Equity ratio of 10.22 is on the low side compared to the rest of the industry. ALNY is outperformed by 82.45% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 10.22 | ||
| Debt/FCF | 11.32 | ||
| Altman-Z | 6.24 |
ROIC/WACC0.75
WACC8.49%
2.3 Liquidity
A Current Ratio of 2.54 indicates that ALNY has no problem at all paying its short term obligations.
The Current ratio of ALNY (2.54) is worse than 70.38% of its industry peers.
ALNY has a Quick Ratio of 2.49. This indicates that ALNY is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.49, ALNY is not doing good in the industry: 68.68% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.54 | ||
| Quick Ratio | 2.49 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 119.47% over the past year.
Looking at the last year, ALNY shows a very strong growth in Revenue. The Revenue has grown by 53.24%.
The Revenue has been growing by 59.21% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)119.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%342.53%
Revenue 1Y (TTM)53.24%
Revenue growth 3Y38.61%
Revenue growth 5Y59.21%
Sales Q2Q%149.35%
3.2 Future
The Earnings Per Share is expected to grow by 69.83% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 33.34% on average over the next years. This is a very strong growth
EPS Next Y186.28%
EPS Next 2Y128.19%
EPS Next 3Y100.69%
EPS Next 5Y69.83%
Revenue Next Year67.6%
Revenue Next 2Y54.86%
Revenue Next 3Y45.29%
Revenue Next 5Y33.34%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 785.47, the valuation of ALNY can be described as expensive.
Based on the Price/Earnings ratio, ALNY is valued cheaper than 88.49% of the companies in the same industry.
When comparing the Price/Earnings ratio of ALNY to the average of the S&P500 Index (26.92), we can say ALNY is valued expensively.
Based on the Price/Forward Earnings ratio of 57.57, the valuation of ALNY can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ALNY indicates a rather cheap valuation: ALNY is cheaper than 90.19% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.46. ALNY is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 785.47 | ||
| Fwd PE | 57.57 |
4.2 Price Multiples
89.25% of the companies in the same industry are more expensive than ALNY, based on the Enterprise Value to EBITDA ratio.
90.75% of the companies in the same industry are more expensive than ALNY, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 239.07 | ||
| EV/EBITDA | 160.33 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates ALNY does not grow enough to justify the current Price/Earnings ratio.
The decent profitability rating of ALNY may justify a higher PE ratio.
ALNY's earnings are expected to grow with 100.69% in the coming years. This may justify a more expensive valuation.
PEG (NY)4.22
PEG (5Y)N/A
EPS Next 2Y128.19%
EPS Next 3Y100.69%
5. Dividend
5.1 Amount
ALNY does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
400.59
-0.1 (-0.02%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners99.74%
Inst Owner Change1.8%
Ins Owners0.21%
Ins Owner Change7.66%
Market Cap52.92B
Revenue(TTM)3.21B
Net Income(TTM)43.56M
Analysts78.92
Price Target496.41 (23.92%)
Short Float %3.05%
Short Ratio3.54
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)103.88%
Min EPS beat(2)30.6%
Max EPS beat(2)177.15%
EPS beat(4)3
Avg EPS beat(4)65.69%
Min EPS beat(4)-2.21%
Max EPS beat(4)177.15%
EPS beat(8)7
Avg EPS beat(8)53.79%
EPS beat(12)10
Avg EPS beat(12)49.23%
EPS beat(16)10
Avg EPS beat(16)28.59%
Revenue beat(2)2
Avg Revenue beat(2)20.36%
Min Revenue beat(2)15.49%
Max Revenue beat(2)25.23%
Revenue beat(4)2
Avg Revenue beat(4)9.94%
Min Revenue beat(4)-0.56%
Max Revenue beat(4)25.23%
Revenue beat(8)4
Avg Revenue beat(8)11.04%
Revenue beat(12)7
Avg Revenue beat(12)14.54%
Revenue beat(16)8
Avg Revenue beat(16)8.99%
PT rev (1m)0.87%
PT rev (3m)11.72%
EPS NQ rev (1m)-4.42%
EPS NQ rev (3m)-23.77%
EPS NY rev (1m)28.6%
EPS NY rev (3m)60.93%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.29%
Revenue NY rev (1m)2.71%
Revenue NY rev (3m)7.09%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 785.47 | ||
| Fwd PE | 57.57 | ||
| P/S | 16.49 | ||
| P/FCF | 239.07 | ||
| P/OCF | 199.06 | ||
| P/B | 226.26 | ||
| P/tB | 226.26 | ||
| EV/EBITDA | 160.33 |
EPS(TTM)0.51
EY0.13%
EPS(NY)6.96
Fwd EY1.74%
FCF(TTM)1.68
FCFY0.42%
OCF(TTM)2.01
OCFY0.5%
SpS24.3
BVpS1.77
TBVpS1.77
PEG (NY)4.22
PEG (5Y)N/A
Graham Number4.51
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.9% | ||
| ROE | 18.63% | ||
| ROCE | 8.03% | ||
| ROIC | 6.34% | ||
| ROICexc | 36.59% | ||
| ROICexgc | 36.59% | ||
| OM | 8.25% | ||
| PM (TTM) | 1.36% | ||
| GM | 83.9% | ||
| FCFM | 6.9% |
ROA(3y)-16.65%
ROA(5y)-19.71%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.88%
GM growth 5Y-0.68%
F-Score5
Asset Turnover0.66
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 10.22 | ||
| Debt/FCF | 11.32 | ||
| Debt/EBITDA | 7.44 | ||
| Cap/Depr | 79.01% | ||
| Cap/Sales | 1.39% | ||
| Interest Coverage | 2.25 | ||
| Cash Conversion | 82.82% | ||
| Profit Quality | 508.12% | ||
| Current Ratio | 2.54 | ||
| Quick Ratio | 2.49 | ||
| Altman-Z | 6.24 |
F-Score5
WACC8.49%
ROIC/WACC0.75
Cap/Depr(3y)112.53%
Cap/Depr(5y)140.08%
Cap/Sales(3y)3.96%
Cap/Sales(5y)7.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)119.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%342.53%
EPS Next Y186.28%
EPS Next 2Y128.19%
EPS Next 3Y100.69%
EPS Next 5Y69.83%
Revenue 1Y (TTM)53.24%
Revenue growth 3Y38.61%
Revenue growth 5Y59.21%
Sales Q2Q%149.35%
Revenue Next Year67.6%
Revenue Next 2Y54.86%
Revenue Next 3Y45.29%
Revenue Next 5Y33.34%
EBIT growth 1Y240.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year548.09%
EBIT Next 3Y166.8%
EBIT Next 5Y135.27%
FCF growth 1Y432.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13193.2%
OCF growth 3YN/A
OCF growth 5YN/A
ALNYLAM PHARMACEUTICALS INC / ALNY FAQ
Can you provide the ChartMill fundamental rating for ALNYLAM PHARMACEUTICALS INC?
ChartMill assigns a fundamental rating of 6 / 10 to ALNY.
What is the valuation status of ALNYLAM PHARMACEUTICALS INC (ALNY) stock?
ChartMill assigns a valuation rating of 5 / 10 to ALNYLAM PHARMACEUTICALS INC (ALNY). This can be considered as Fairly Valued.
How profitable is ALNYLAM PHARMACEUTICALS INC (ALNY) stock?
ALNYLAM PHARMACEUTICALS INC (ALNY) has a profitability rating of 6 / 10.
What is the financial health of ALNYLAM PHARMACEUTICALS INC (ALNY) stock?
The financial health rating of ALNYLAM PHARMACEUTICALS INC (ALNY) is 5 / 10.
What is the expected EPS growth for ALNYLAM PHARMACEUTICALS INC (ALNY) stock?
The Earnings per Share (EPS) of ALNYLAM PHARMACEUTICALS INC (ALNY) is expected to grow by 186.28% in the next year.